iRadimed (FRA:46K) Tariff Resilience Score: 7/10 (As of Jul. 11, 2026)


FRA:46K iRadimed Corp FRA:46K
87 GF Score
Price €84.50
GF Value €56.24
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is iRadimed Tariff Resilience Score?

iRadimed FRA:46K +1.81% 87 Tariff Resilience Score is 7 as of Jul. 11, 2026. GuruFocus rates FRA:46K with a GF Score™ of 87/100 and a GF Value™ of €56.24 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 835 Medical Devices & Instruments companies, iRadimed ranks better than 98.08% on this metric.

iRadimed has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

iRadimed has iRadimed Corp has a moderate global supply chain dependency with some manufacturing overseas. However, its primary market is the U.S., reducing tariff impact. Historical data shows limited impact from tariffs, and the company has alternative suppliers and strong pricing power.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes iRadimed might have Highly Resilient.

iRadimed  (FRA:46K) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

iRadimed Tariff Resilience Score Related Terms

FRA:46K vs AVNS, LMRI, AORT: Tariff Resilience Score Comparison

For the Medical Devices subindustry, iRadimed's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iRadimed Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where iRadimed's Tariff Resilience Score falls into.


FRA:46K
87GF Score
iRadimed Corp FRA:46K
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
iRadimed (FRA:46K) has a Tariff Resilience Score of 7 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, iRadimed ranks #16 out of 835 companies in the Medical Devices & Instruments industry, placing it in the top 1.9%.
Is iRadimed's Tariff Resilience Score too high?
iRadimed's current Tariff Resilience Score is 7. Based on the distribution chart, iRadimed ranks #16 out of 835 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, iRadimed has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's Tariff Resilience Score compare to AVNS and LMRI?
According to the Medical Devices & Instruments industry distribution chart, iRadimed ranks #16 out of 835 companies for Tariff Resilience Score. This places iRadimed in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. iRadimed's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €56.24, compared to a current price of €84.50 — trading 50.2% above its estimated fair value. The current Tariff Resilience Score is 7. iRadimed's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For iRadimed (FRA:46K), the current Tariff Resilience Score is 7 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iRadimed (FRA:46K) Overvalued in 2026?

Based on GuruFocus' analysis, iRadimed stock appears to be overvalued. The current stock price of €84.50 is trading 50.2% above its estimated GF Value™ of €56.24. GuruFocus considers iRadimed to be Significantly Overvalued.

Key valuation signals for FRA:46K:

  • Tariff Resilience Score: 7
  • GF Value™: €56.24 vs. price of €84.50 (50.2% above fair value)
  • GF Score™: 87/100 with 6 warning signs

No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iRadimed Business Description

Other Exchanges IRMD:USA
Address 12705 Ingenuity Drive, Orlando, FL, USA, 32826
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
87GF Score

Get the complete analysis for FRA:46K

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€84.50
Price
€56.24
GF Value